Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors

Edward M. Wolin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background/Aims: Based on the significant prolongation of progression-free survival in a randomized phase III trial, RADIANT-3 (RAD001 in Advanced Neuroendocrine Tumors, Third Trial), everolimus has been approved for the management of advanced, progressive pancreatic neuroendocrine tumors (pNET). Here, we describe 15 participants in RADIANT-3 who were treated with everolimus at our study center. We report the long-term survival of a subset of patients. Methods: Patients with advanced, progressive pNET were randomly assigned to the everolimus arm of RADIANT-3 or received everolimus as open-label treatment after experiencing progression on placebo or during the unblinded phase. Results: Five patients on everolimus (5-10 mg/day) had stable disease for >43 to >76 months after initiating treatment. Three patients achieved stable disease for 19-25 months, but died of progressive malignancy thereafter. Seven patients had stable disease for ≤11 months after initiating everolimus therapy. Conclusion: Patients with advanced, progressive pNET can obtain long-term benefit from daily oral treatment with everolimus.

Original languageEnglish (US)
Pages (from-to)143-150
Number of pages8
JournalChemotherapy
Volume60
Issue number3
DOIs
StatePublished - Apr 24 2014
Externally publishedYes

Fingerprint

Neuroendocrine Tumors
Therapeutics
Everolimus
Disease-Free Survival
Placebos
Survival

Keywords

  • Everolimus
  • Neuroendocrine tumors
  • Pancreatic cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors. / Wolin, Edward M.

In: Chemotherapy, Vol. 60, No. 3, 24.04.2014, p. 143-150.

Research output: Contribution to journalArticle

Wolin, Edward M. / Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors. In: Chemotherapy. 2014 ; Vol. 60, No. 3. pp. 143-150.
@article{0af33fa487ae48feb7a6c6ba922bbc96,
title = "Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors",
abstract = "Background/Aims: Based on the significant prolongation of progression-free survival in a randomized phase III trial, RADIANT-3 (RAD001 in Advanced Neuroendocrine Tumors, Third Trial), everolimus has been approved for the management of advanced, progressive pancreatic neuroendocrine tumors (pNET). Here, we describe 15 participants in RADIANT-3 who were treated with everolimus at our study center. We report the long-term survival of a subset of patients. Methods: Patients with advanced, progressive pNET were randomly assigned to the everolimus arm of RADIANT-3 or received everolimus as open-label treatment after experiencing progression on placebo or during the unblinded phase. Results: Five patients on everolimus (5-10 mg/day) had stable disease for >43 to >76 months after initiating treatment. Three patients achieved stable disease for 19-25 months, but died of progressive malignancy thereafter. Seven patients had stable disease for ≤11 months after initiating everolimus therapy. Conclusion: Patients with advanced, progressive pNET can obtain long-term benefit from daily oral treatment with everolimus.",
keywords = "Everolimus, Neuroendocrine tumors, Pancreatic cancer",
author = "Wolin, {Edward M.}",
year = "2014",
month = "4",
day = "24",
doi = "10.1159/000369780",
language = "English (US)",
volume = "60",
pages = "143--150",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors

AU - Wolin, Edward M.

PY - 2014/4/24

Y1 - 2014/4/24

N2 - Background/Aims: Based on the significant prolongation of progression-free survival in a randomized phase III trial, RADIANT-3 (RAD001 in Advanced Neuroendocrine Tumors, Third Trial), everolimus has been approved for the management of advanced, progressive pancreatic neuroendocrine tumors (pNET). Here, we describe 15 participants in RADIANT-3 who were treated with everolimus at our study center. We report the long-term survival of a subset of patients. Methods: Patients with advanced, progressive pNET were randomly assigned to the everolimus arm of RADIANT-3 or received everolimus as open-label treatment after experiencing progression on placebo or during the unblinded phase. Results: Five patients on everolimus (5-10 mg/day) had stable disease for >43 to >76 months after initiating treatment. Three patients achieved stable disease for 19-25 months, but died of progressive malignancy thereafter. Seven patients had stable disease for ≤11 months after initiating everolimus therapy. Conclusion: Patients with advanced, progressive pNET can obtain long-term benefit from daily oral treatment with everolimus.

AB - Background/Aims: Based on the significant prolongation of progression-free survival in a randomized phase III trial, RADIANT-3 (RAD001 in Advanced Neuroendocrine Tumors, Third Trial), everolimus has been approved for the management of advanced, progressive pancreatic neuroendocrine tumors (pNET). Here, we describe 15 participants in RADIANT-3 who were treated with everolimus at our study center. We report the long-term survival of a subset of patients. Methods: Patients with advanced, progressive pNET were randomly assigned to the everolimus arm of RADIANT-3 or received everolimus as open-label treatment after experiencing progression on placebo or during the unblinded phase. Results: Five patients on everolimus (5-10 mg/day) had stable disease for >43 to >76 months after initiating treatment. Three patients achieved stable disease for 19-25 months, but died of progressive malignancy thereafter. Seven patients had stable disease for ≤11 months after initiating everolimus therapy. Conclusion: Patients with advanced, progressive pNET can obtain long-term benefit from daily oral treatment with everolimus.

KW - Everolimus

KW - Neuroendocrine tumors

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84928422914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928422914&partnerID=8YFLogxK

U2 - 10.1159/000369780

DO - 10.1159/000369780

M3 - Article

C2 - 25766415

AN - SCOPUS:84928422914

VL - 60

SP - 143

EP - 150

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 3

ER -